Innovation In The Age Of Breast-Conserving Surgery

Medical device and diagnostic companies are developing innovative new products for women with breast cancer designed to facilitate earlier diagnosis, improve diagnostic accuracy, increase surgical precision, and enable the least invasive, most breast-conserving approach to breast cancer surgery. With the number of breast cancer cases in the US projected to increase dramatically by 2030, the success of these technologies depends on their ability to improve cosmetic results and survival rates while lowering overall health care costs.

Earlier this year, the American Association for Cancer Research (AACR) presented statistics from the National Cancer Institute (NCI) showing that the number of breast cancer cases in the US is expected to be 50% higher in 2030 than it was in 2011, increasing from a total of 283,000 cases to 441,000 cases. In 2015 alone, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the US, in addition to 60,290 new cases of noninvasive, ductal carcinoma in situ (DCIS) breast cancer, according to the most recent statistics from the American Cancer Society. Moreover, this year, 40,290 women in the US are expected to die of breast cancer.

Although the overall number of breast cancer cases is growing, the most difficult-to-treat breast cancer, estrogen-receptor (ER)-negative cancer, is declining in proportional terms. According to data from the NCI presented...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Surgical Procedures

Bone Surgery Startup Surgify Medical Raises $7.9m

 

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By 

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

More from Surgery

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

AAOS 2025 Orthopedic Roundup: J&J Velys UKA, Stryker Mako 4, Materialise, Canary Medical

 
• By 

At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.